- Jasper Therapeutics (JSPR, Financial) to present four key abstracts on briquilimab at EAACI Congress 2025.
- Focus on briquilimab's efficacy in treating mast cell driven diseases including urticaria and asthma.
- Presentations scheduled for June 14-15, 2025, in Glasgow, UK.
Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, has announced the acceptance of four abstracts for presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow. The presentations will highlight the company's novel antibody therapy, briquilimab, which targets c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.
The presentations will take place on June 14-15, 2025, and will include initial clinical data from the SPOTLIGHT Phase 1b/2a study. This study evaluates briquilimab's effects in patients with cold urticaria and symptomatic dermographism who remain symptomatic despite H-1 antihistamine treatment. A notable presentation will include updated results demonstrating "rapid, clinically meaningful disease-control" in CSU, suggesting promising efficacy signals for briquilimab.
Jasper is also set to present preclinical findings on briquilimab's protective effects against allergen-induced dermatitis in mice and its mitigating effects on COPD-like features in asthma models. These findings are part of Jasper's broader exploration of briquilimab's potential applications beyond urticaria, aiming to establish it as a platform therapy for multiple allergic and inflammatory conditions.
Jasper Therapeutics continues to focus on clinical developments in briquilimab as a therapeutic option for mast cell related disorders, positioning itself as a key player in the field of allergy and inflammation therapeutics.
